Half-year report · Q2
9273.TEDINET S100V85J
Period2024-07-01 → 2024-12-31
Filed2025-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.3bn | 2024-07-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥22.1bn | 2023-07-01 → 2024-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.4bn | 2023-07-01 → 2023-12-31 | Cons. | Net sales |
| Operating income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Operating income |
| Operating income | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.4bn | 2023-07-01 → 2024-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.9bn | 2023-07-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.6bn | 2023-07-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss |
| Net income | ¥1.6bn | 2023-07-01 → 2023-12-31 | Cons. | Profit loss |
| Total assets | ¥33.6bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥32.0bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥29.6bn | at 2023-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.0bn | at 2024-12-31 | Cons. | Liabilities |
| Total liabilities | ¥7.0bn | at 2024-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥26.6bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥25.1bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥22.0bn | at 2023-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥12.5bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.0bn | at 2024-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥9.8bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.2bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.3bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.0bn | at 2023-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.0bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.8bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.5bn | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.7bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.5bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥644m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥738m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥795m | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥639m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥48.66 | 2024-07-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.14 | 2023-07-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.46 | 2023-07-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 79.1% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.3% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.2% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2024-12-31 | ¥81m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥8.0bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥7.4bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.6bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.4bn |
| —segment total | revenue | 2024-07-01 → 2024-12-31 | ¥12.9bn |
| —segment total | revenue external | 2024-07-01 → 2024-12-31 | ¥12.3bn |
| —segment total | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| —segment total | segment profit | 2024-07-01 → 2024-12-31 | ¥3.0bn |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-12-31 | −¥871m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-12-31 | −¥871m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-12-31 | −¥38m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥7.9bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥7.0bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥871m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1.0bn |
| —segment total | revenue | 2023-07-01 → 2023-12-31 | ¥12.3bn |
| —segment total | revenue external | 2023-07-01 → 2023-12-31 | ¥11.4bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥871m |
| —segment total | segment profit | 2023-07-01 → 2023-12-31 | ¥2.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 494
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)東 陽 監 査 法 人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)田 部 秀 穂 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)阿 久 津 大 輔 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 11382942000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 12259451000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 22134145000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 2440109000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 3065617000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 4368056000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 1563306000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 2049328000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 2946337000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 1537530000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 2053876000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 2970659000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 21985595000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 26558008000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 25051674000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 29642592000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 33575928000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 32004016000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 39.46 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 48.66 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 74.14 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.7417 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.7910 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.7828 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 1540318000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 1008316000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 3830664000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -644320000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -3705028000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -1471124000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -639109000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -737872000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 795246000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 10291783000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 9751143000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 13195373000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 42119980 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 42119980 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 42119980 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 42119980 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 17829000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.4233 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |